Neuphoria Therapeutics Inc. (NEUP) Stock Score, Valuation & Financial Research
Neuphoria Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 43/100.
Quick answer for NEUP
Neuphoria Therapeutics Inc. currently has a Wall Street Score of 43/100. The stored market price is $3.7. Its financial score is 32/100. Its valuation score is 0/100. The latest WSS change is -3.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Neuphoria Therapeutics Inc. does
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
NEUP financial snapshot
- Wall Street Score:
- 43/100
- Current price:
- $3.7
- Market capitalization:
- $20.0M
- Revenue:
- $-10.5M
- Net income:
- $-28.5M
- Free cash flow:
- $-12.35B
- Cash:
- $19.4M
- Total debt:
- $34K
- EPS:
- -11.00
- Financial score:
- 32/100
- Valuation score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -1.0%.
- Free cash flow is $-12.35B, showing cash burn in the current stored period.
- The balance sheet shows $19.4M of cash versus $34K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -3.1 points: NEUP decreased 3.1 points because some fundamentals weakened.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
Questions worth answering for NEUP
These questions are derived from the company's current stored financial and score data so the page adds company-specific research context instead of treating the headline score as a stand-alone conclusion.
- What is driving NEUP's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
- How long can NEUP fund negative free cash flow using its current cash position before it may need more debt or new shares?
- How is NEUP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- What specifically needs to improve for NEUP to reach sustainable profitability?
- What future growth or profitability would be needed to justify NEUP's current valuation?
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-19.
Research-input completeness: 82% of the scoring inputs required for this public page are currently available.
How to research NEUP
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.